GlassScriptPhysician profile
Robert J Ellis
NPI 1720056823
$2,920.37
in general payments reported to CMS, 2019-2025
37 companies · $933 in 2025
The $933 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $37.09 · 2021: $310 · 2022: $496 · 2023: $609 · 2024: $410 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.54 |
| Education | $215.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $298.70 | 2023-2025 | Enhertu, Imfinzi |
| Janssen Biotech, INC. | $295.89 | 2022-2023 | Darzalex, Erleada, Balversa |
| Gilead Sciences, INC. | $210.79 | 2021-2024 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $157.11 | 2021-2025 | Opdualag, Opdivo, Krazati |
| Tempus Ai, INC | $154.23 | 2024-2025 | Xt Cdx |
| Eisai INC. | $154.08 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $130.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.24 | 2025 | |
| Cti Biopharma Corp. | $117.42 | 2022 | |
| Celgene Corporation | $108.73 | 2023-2025 | Reblozyl, Pomalyst |
| Stemline Therapeutics INC. | $106.33 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $97.37 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.98 | 2023 | |
| Puma Biotechnology, INC. | $93.68 | 2023 | Nerlynx |
| Epizyme, INC. | $86.72 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $79.39 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $67.80 | 2022-2025 | |
| Exelixis INC. | $62.44 | 2019 | |
| Lilly USA, LLC | $53.31 | 2019-2024 | Verzenio |
| Genentech, INC. | $49.95 | 2021 | |
| Merck Sharp & Dohme LLC | $46.48 | 2024 | Keytruda |
| Medtronic, INC. | $38.87 | 2021 | |
| Pfizer INC. | $37.92 | 2023-2025 | |
| Medinc of Texas | $33.53 | 2025 | |
| Daiichi Sankyo INC. | $26.17 | 2025 | Enhertu |
| Array Biopharma INC | $26.05 | 2025 | Braftovi, Lorbrena, Xtandi |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Foundation Medicine, INC. | $25.00 | 2019 | |
| Biogen, INC. | $22.22 | 2020 | |
| Beone Medicines USA, INC. | $21.86 | 2025 | Brukinsa |
| Sobi, INC | $17.46 | 2022 | |
| Glaxosmithkline, LLC. | $15.82 | 2025 | Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $14.87 | 2020 | |
| Genzyme Corporation | $14.52 | 2023 | |
| Dendreon Pharmaceuticals LLC | $12.12 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.